Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3672
Source ID: NCT01821846
Associated Drug: Liraglutide
Title: Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: liraglutide
Outcome Measures: Primary: The incidence of SADRs (Serious Adverse Drug Reactions), Up to 6 months | Secondary: HbA1c (Glycosylated haemoglobin) change, Month 0, month 6|Percentage of subjects reaching the target of HbA1c below 7.0%, Month 6|Change in body weight, Month 0, month 6|Number of SAEs/ ADRs (Serious Adverse Events/Adverse Drug Reactions), Up to 6 months
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: CHILD, ADULT, OLDER_ADULT
Phases:
Enrollment: 64
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2013-11-20
Completion Date: 2017-03-08
Results First Posted:
Last Update Posted: 2017-08-21
Locations: Novo Nordisk Investigational Site, Pyungchon-Dong 896, Dongan-Gu, 431-796, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 02447, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 03080, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, 150-950, Korea, Republic of|Novo Nordisk Investigational Site, Ulsan, 44455, Korea, Republic of|Novo Nordisk Investigational Site, Ulsan, 682-060, Korea, Republic of|Novo Nordisk Investigational Site, Wonju, 220-701, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT01821846

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress